ETV5 and obesity disorder: Indeed, MLN4924 attenuates HFD-induced ETV5 degradation (Fig. 7a), obesity (Fig. 7b), hyperinsulinemia (Fig. 7c), hyperglycemia (Fig. 7d), glucose intolerance (Fig. S5b), and insulin resistance (Fig. S5c).